Get Support

Learn Mode

BIIB - Biogen Inc

75

$183.33

-$4.24 (-2.260%)

At close: 3/31/26, 8:00 PM

3.45/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

BIIB

Valuation Score

View as %

Stock Unlock

1D

1W

1M

YTD

1Y

3Y

5Y

Max

Stock Profile

Market Cap

$26.91B

Industry

Biotechnology

EPS (TTM)

$8.81

P/E (TTM)

20.81

Div & Yield

--

FCF Payout Ratio

--

P/S (TTM)

2.72

P/B

1.47

Diluted Shares

146.80M

Ex-Dividend

--

Next Earnings

04-29

Forward P/E

11.04

Payout Ratio

--

P/FCF (TTM)

13.32

FCF Yield

7.50%

Earnings Yield

4.81%

52 Week Range

Score Card

Explore Scores Tab

3.45

Good

Biogen Inc has grown revenue at 2.22% over the past year, which suggests sales are increasing. Also, it has more cash than current liabilities meaning it has enough cash to handle all its debts within the next year, if it wanted to.

Valuation Model

Key Score

1.00

Very Bad

Management

2.00

Bad

Growth

1.00

Very Bad

Profitability

1.00

Very Bad

Fin. Health

3.00

Average

Dividends

--

--

Analyst

2.00

Bad

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

1 new filing was in the last 7 days

Filter Form Types

Form SCHEDULE 13G/A

Unknown Form Type

Filed on 2026-03-26 16:09:29

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-03-11 17:28:01

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-17 20:18:48

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-17 20:17:51

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-17 20:16:40

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-17 20:14:49

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-17 20:12:09

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-17 20:11:16

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-17 20:10:17

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-17 20:09:09

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-17 20:07:57

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-17 20:05:49

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-03-25

High:

$273.00

48.9%

Avg:

$210.62

14.9%

Low:

$151.50

-17.4%

(% change is relative to the current stock price: $183.33)

Analyst Recommendations

Go to Analyst Tab

3.65

Good

21%

Strong Buy (9)

26%

Buy (11)

51%

Hold (22)

2%

Sell (1)

0%

Strong Sell (0)

About

Website
https://www.biogen.com/
Address
225 Binney Street, Cambridge MASSACHUSETTS, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=875045

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 7,500 full-time employees. The firm is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. The company operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). The company is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. The company also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).

IPO Date

1991-09-17

Industry

Biotechnology

Total Employees

7,605

Exchange

Nasdaq Nms - Global Market

Reporting Currency

USD

GICS

Biotechnology

GICS Sub

Biotechnology

GICS Sector

Health Care

GICS Group

Pharmaceuticals, Biotechnology & Life Sciences